title: Plasmin Enzyme-Assisted Vitrectomy in Pediatric Patients with Vitreoretinal Diseases.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of using plasmin-assisted vitrectomy in pediatric patients with vitreoretinal diseases.
  
  
  METHODS
  We prospectively recruited children aged 16 years or younger who presented with vitreoretinopathies and underwent plasmin-assisted vitrectomy between 2012 and 2013. The main outcome measure was the induction of posterior vitreous detachment (PVD) using a suction power of 200 mm Hg or less during surgery.
  
  
  RESULTS
  Eleven eyes of 11 patients (mean age: 3.7 years; average follow-up duration: 14.1 months) were included. Of these 11 patients, there were 3 (27%) cases of stage 5 retinopathy of prematurity, 2 (18%) cases of persistent fetal vasculature, 2 (18%) cases of rhegmatogenous retinal detachment, 2 (18%) cases of idiopathic epiretinal membrane, 1 (9%) case of traumatic macular pucker, and 1 (9%) case of traumatic vitreous hemorrhage (9%). PVD was achieved in all cases (100%) during surgery using low suction after plasmin treatment (mean: 150 ± 39 mm Hg; range: 100-200). Overall, anatomical success was achieved in 8 eyes (73%). Visual acuity improved in all 5 (100%) patients for whom vision could be measured at 6 months after the operation. Cataracts were found in 4 eyes (36%), and a rise in transient intraocular pressure was observed in 1 eye (9%).
  
  
  CONCLUSIONS
  Plasmin-assisted vitrectomy offers an effective and less traumatic intervention for a variety of pediatric vitreoretinal diseases.
authors: Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou, Taiwan, ROC.
authors: Yung-Sung
authors: YS
authors: Lee
authors: Nan-Kai
authors: NK
authors: Wang
authors: Yen-Po
authors: YP
authors: Chen
authors: Kuan-Jen
authors: KJ
authors: Chen
authors: Yih-Shiou
authors: YS
authors: Hwang
authors: Chi-Chun
authors: CC
authors: Lai
authors: Wei-Chi
authors: WC
authors: Wu
mesh_terms: D002648:Child; D002675:Child, Preschool; D015862:Choroid Diseases / Q000175:diagnosis / Q000503:physiopathology / Q000601:surgery*; D015785:Eye Diseases, Hereditary / Q000175:diagnosis / Q000503:physiopathology / Q000601:surgery*; D005260:Female; D005341:Fibrinolysin / Q000494:pharmacology*; D005343:Fibrinolytic Agents / Q000494:pharmacology; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D009887:Ophthalmoscopy; D011446:Prospective Studies; D012160:Retina / Q000000981:diagnostic imaging; D012162:Retinal Degeneration / Q000175:diagnosis / Q000503:physiopathology / Q000601:surgery*; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity; D014821:Vitrectomy / Q000379:methods*
chemical_list: D005343:Fibrinolytic Agents; D005341:Fibrinolysin